Advertisement
A live Web cast of the presentation will be available online from theinvestor relations page of the Company's corporate Web site atwww.nuvasive.com. After the live Web cast, the presentation will remainavailable on NuVasive's Web site, www.nuvasive.com, for 30 days.
Advertisement
About NuVasive
NuVasive is a medical device company focused on the design, developmentand marketing of products for the surgical treatment of spine disorders. TheCompany's product portfolio is focused on applications in the over $4.2billion U.S. spine fusion market. The Company's current principal productoffering includes a minimally disruptive surgical platform called MaximumAccess Surgery, or MAS(R), as well as a growing offering of cervical andmotion preservation products.
The MAS platform offers advantages for both patients and surgeons such asreduced surgery and hospitalization time and faster recovery. MAS combinesthree categories of current product offerings: NeuroVision(R) a proprietarysoftware-driven nerve avoidance system; MaXcess(R) a unique split-blade designretraction system; and specialized implants, like SpheRx(R) and CoRoent(R),that collectively minimize soft tissue disruption during spine surgery whileallowing maximum visualization and surgical reproducibility. NuVasive'sproduct offering is also focused on cervical internal fixation products andits R&D pipeline emphasizes both MAS and motion preservation.
NuVasive cautions you that statements included in this press release thatare not a description of historical facts are forward-looking statements thatinvolve risks, uncertainties, assumptions and other factors which, if they donot materialize or prove correct, could cause NuVasive's results to differmaterially from historical results or those expressed or implied by suchforward-looking statements. The potential risks and uncertainties that couldcause actual growth and results to differ materially include, but are notlimited to: the uncertain process of seeking regulatory approval or clearancefor NuVasive's products or devices, including risks that such process could besignificantly delayed; the possibility that the FDA may require significantchanges to NuVasive's products or clinical studies; the risk that products maynot perform as intended and may therefore not achieve commercial success; therisk that competitors may develop superior products or may have a greatermarket position enabling more successful commercialization; the risk thatadditional clinical data may call into question the benefits of NuVasive'sproducts to patients, hospitals and surgeons; and other risks anduncertainties more fully described in NuVasive's press releases and periodicfilings with the Securities and Exchange Commission. NuVasive's public filingswith the Securities and Exchange Commission are available at www.sec.gov.NuVasive assumes no obligation to update any forward-looking statement toreflect events or circumstances arising after the date on which it was made.Contact: Investors: Kevin C. O'Boyle Nick Laudico/Zack Kubow EVP & Chief Financial Officer The Ruth Group NuVasive, Inc. 646-536-7030/7020 858-909-1800 [email protected] [email protected] [email protected] Media: Jason Rando The Ruth Gr
